Technical advance

An approach to analyse the specific impact of rapamycin on mRNA-ribosome association

Raphael Genolet, Tanguy Araud, Laetitia Maillard, Pascale Jaquier-Gubler and Joseph Curran*

Address: Department of Microbiology and Molecular Medicine, University of Geneva Medical School (CMU), 1 rue Michel Servet, CH-1211 Geneva, Switzerland

Email: Raphael Genolet - Raphael.Genolet@medecine.unige.ch; Tanguy Araud - Tanguy.Araud@medecine.unige.ch; Laetitia Maillard - Laetitia.Maillard@adm.unige.ch; Pascale Jaquier-Gubler - Pascale.Jaquier-Gubler@medecine.unige.ch; Joseph Curran* - Joseph.Curran@medecine.unige.ch

* Corresponding author

Published: 1 August 2008
Received: 7 March 2008
Accepted: 1 August 2008

© 2008 Genolet et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Recent work, using both cell culture model systems and tumour derived cell lines, suggests that the differential recruitment into polysomes of mRNA populations may be sufficient to initiate and maintain tumour formation. Consequently, a major effort is underway to use high density microarray profiles to establish molecular fingerprints for cells exposed to defined drug regimes. The aim of these pharmacogenomic approaches is to provide new information on how drugs can impact on the translational read-out within a defined cellular background.

Methods: We describe an approach that permits the analysis of de-novo mRNA-ribosome association in-vivo during short drug exposures. It combines hypertonic shock, polysome fractionation and high-throughput analysis to provide a molecular phenotype of translationally responsive transcripts. Compared to previous translational profiling studies, the procedure offers increased specificity due to the elimination of the drugs secondary effects (e.g. on the transcriptional read-out). For this pilot ”proof-of-principle” assay we selected the drug rapamycin because of its extensively studied impact on translation initiation.

Results: High throughput analysis on both the light and heavy polysomal fractions has identified mRNAs whose re-recruitment onto free ribosomes responded to short exposure to the drug rapamycin. The results of the microarray have been confirmed using real-time RT-PCR. The selective down-regulation of TOP transcripts is also consistent with previous translational profiling studies using this drug.

Conclusion: The technical advance outlined in this manuscript offers the possibility of new insights into mRNA features that impact on translation initiation and provides a molecular fingerprint for transcript-ribosome association in any cell type and in the presence of a range of drugs of interest. Such molecular phenotypes defined pre-clinically may ultimately impact on the evaluation of a particular drug in a living cell.
Background
Dissecting the specific effect of a drug on a defined biological process is often complicated by the plethora of secondary effects that arise during extended exposure. This is highlighted by the anti-cancer drug rapamycin whose principle, although not exclusive, target is the rate limiting initiation step of protein translation [1]. Techniques designed to analyse the effect of the drug on mRNA-ribosome association are hampered by the long exposure times required to observe changes in the polysomal mRNA populations. Translation initiation is frequently regulated via the eukaryotic initiation factor 4E (eIF4E). It can be sequestered into an inactive complex by a family of 4E-binding proteins (4E-BP1/2/3). The affinity of these proteins for eIF4E is modulated by phosphorylation via the mTORC1 (mammalian target of rapamycin complex 1) kinase [2]. Rapamycin arrests many cells in G1 [3], and is a potent immunosuppressant [4]. It exerts its action by binding and inactivating the mTORC1 [5]. Previous studies have shown that extended exposure to rapamycin also alters transcription. Among the mRNAs regulated, a number impact directly on translation (e.g. eIF2α) [6]. These changes were minor after short drug exposure times (< 60 mins), but increased markedly after 2 hrs. Translational profiling studies (which examine the mRNAs associated with ribosomes) have also been reported [7-10]. One study, performed on the Jurkat T cell clone E6-1, revealed that after an extended exposure to rapamycin (minimum 4 hrs) almost all transcripts analysed were inhibited, and 136 of those (representing ~5% of the total) were strongly inhibited (at least 10 fold). This latter group included a number of mRNAs whose products impact directly on translation (e.g. elf5A, elf4A1, elf1, elf1tu) [8]. This would predict that lengthy exposure to the drug will influence translation by modifying the levels of initiation and elongation factors. We therefore sought to develop a technique that would permit a specific analysis on how the drug alters transcript recruitment onto free ribosomes under conditions that eliminated the secondary effects associated with extended exposure. The approach has been coupled to a high-throughput microarray screen to examine how rapamycin exposure impacts on the re-seeding of the polysomal transcript populations. Results from the array have also been validated by quantitative RT-PCR.

Methods
Cell culture
MRC-5 cells (Coriell Cell Repository) were cultured in Minimal Essential Medium (Gibco) supplemented with 1 mM sodium pyruvate (Sigma), 0.1 mM non-essential amino acids, 10% foetal calf serum (Brunschwig), 1% penicillin/streptomycin, in a humidified atmosphere containing 5% CO2. For polysome analysis, cells in the growing phase (60% confluence) were hypertonically shocked by shifting to medium containing 300 mM NaCl for 50 min. They were then placed in normal isotonic medium for 30 min. When rapamycin was used, 100 nM rapamycin (LC laboratories) or 0.01% DMSO (the negative control) was added during the hypertonic shock, 20 min before the transfer back to isotonic conditions. Rapamycin and DMSO were kept on the cells throughout the 30 mins recovery period (total time of exposure to rapamycin was 50 mins). These conditions were based upon previously published work [11], although we have independently confirmed that they can be used on a range of cell lines including 293T [12], HeLa S3 and SK-NA5 (data not shown).

Polyosome gradient/RNA extraction
After treatment, cells were scraped into the culture medium and pelleted for 4 min at 100 g. The pellets, consisting of 5 × 105 cells, were lysed for 15 min on ice in 400 μL of 100 mM KCl, 50 mM Tris-Cl pH 7.4, 1.5 mM MgCl2, 1 mM DTT, 1 mg/mL heparin, 1.5 % NP40, 100 μM cycloheximide, 1% aprotinin, 1 mM AEBSF and 100 U/mL of RNasin. Nuclei were pelleted by centrifugation in a microfuge, 10 min at 12000 rpm. The supernatant was loaded onto a 20–60% sucrose gradient (in 100 mM KCl, 5 mM MgCl2, 20 mM HEPES pH 7.4 and 2 mM DTT). Extracts were fractionated for 3 h 30 min at 35,000 rpm at 4°C in a Beckman SW41 rotor, and the gradients were recovered in 3 fractions [monosome, light polysome (2 to 5 ribosomes) and heavy polysome (> 5 ribosomes)] using a Brandel gradient fractionator equipped with an ISCO UA-6 flow cell set to 254 nm. RNA was isolated from the light and heavy polysome fractions by adding an equal volume of TriZol (Invitrogen). Samples were mixed and incubate for 15 min. on ice, then 0.3 volumes of chloroform was added. After centrifugation, the upper phase was collected and the RNA precipitated with 0.7 volumes of isopropanol. The pellet of RNA was re-suspended in water. Prior to microarray analysis the pooled RNA fractions were further purified using the Qiagen RNeasy kit. The total yield of RNA in each pooled fraction was ~2 μg. RNA quality was checked on an Agilent 2100 bioanaylsers.

Microarray
Total RNA (100 ng from each fraction) was first amplified using the two step amplification protocol of Affymetrix. cRNA (17.5 μg) was then used to probe the Gene Chip U133 Plus 2.0 with 54,675 probe sets, covering more than 47,000 transcripts. Three biological replicates were hybridised for each condition (light and heavy polysomes +/- rapamycin). Data were analysed using the GCSO normalisation of Affymetrix. After normalisation, we filtered out probe sets that were assayed “absent” in all the 12 arrays. For this, the expression levels in each control experiment (DMSO) were arbitrarily fixed to one, and the fold change of the corresponding probe in the treated samples was calculated.
was normalised to this. The variation was then tested using the Mann and Witney U statistical test. Using this approach 24,105 of the probe sets (44%) were flagged as absent. The data was further analysed using two approaches. Firstly, probe set intensity values below 100 were removed prior to GCOS normalisation, and fold changes ≥ 1.5 relative to the DMSO control were scored (the smallest score in the three independent experiments had to show at least a 20% change relative to the DMSO control i.e. a 1.2 fold increase or a 0.8 fold decrease). In a second approach, commencing with the entire data set, points were only scored if the mean of the fold difference was ≥ 2.5 (once again the smallest score in the three independent experiments had to show at least a 20% change relative to the DMSO control). The data from both screens were plotted onto biological networks using the GO ontology (Affymetrix) and Ingenuity Pathway Analysis Software packages http://www.Ingenuity.com.

The microarray data are available at ArrayExpress (Accession N° E-TABM-205).

**Real-Time PCR**

One μg of total RNA from a fourth independent experiment was reverse transcribed using random hexamers (Gibco). A 1/10 dilution of the cDNA was used to perform the PCR with the SYBR Green Reagent (Roche).

Primers used were:

**QKI** AGCATCACAGTCAGAGGTCAGC, GCAGTGGCATATTAAACCAAAGC;

**RBM7** GTTGAAAAATCAAGCCCTACCT, AATCCTGATTTGATCCAGAGGTG;

**ORMDL1** GTCTGGCAGAAACAACGTCTC, CAATGTGGTTGCTGTTCTGG;

**FAS** GATGGCGAATGAGGTTCAG, CAATCCCATATCTCCCATTAAC;

**RBM17** GTCATCTCCGGTGATCCTTAAA, CAACCAGAGGCACACAGAT;

**PAPPA** GATGGGCAATGAGGTTCAG, CAATCCCATATCTCCCATTAAC;

**Actin** CTGACGGCCAGGTCATCACATTG, GCCGGACTGCATCACTCTGCTG;

**L27** GTGACAGCTGCAATGGCAAG, TCAAACATGACCTTGCCCTCCG,

**Cyclin D1** AAGCAGGACITTTGAGGCA AG, CCTCTGAGGTCCCTACTTCAA.

Primer sets were designed to amplify regions within the 3' UTR of each transcript since this generally corresponded to the site of the probe sets used on the Affymetrix chip. The specificity of each primer set was confirmed by standard RT-PCR on total cell RNA, followed by analysis of the DNA products by agarose gel electrophoresis (data not shown).

**Western blot analysis**

Cells were lysed in CSH buffer (50 mM Tris-Cl pH 7.5, 250 mM NaCl, 1 mM EDTA, 0.1% Triton X-100) and the nuclei were pelleted by centrifugation at 12,000 rpm for 5 mins. Twenty μg of protein was resolved on a 15% poly-acrylamide-SDS gel and electrotransferred to a PVDF membrane. Antibodies used in this study were the anti-4EBP1 (Cell Signalling), the anti-phosho4EBPI (Thr37/46) (Cell Signalling), the anti-p70 S6 kinase (Cell Signalling), the anti-phospho-p70 S6 kinase (Thr389) (Cell Signalling) and mouse anti-actin (Chemicon). Blots were developed using the Super Signal Substrate (Thermo Scientific).

**Results**

**Rapamycin delays mRNA recruitment onto polysomes**

To directly examine the effect of rapamycin on mRNA recruitment we decided to exploit a novel approach, an approach that analyses the ability of cellular mRNAs to compete for free ribosomes in-vivo. Hypertonic shock provokes a rapid inhibition of protein synthesis, disaggregation of polysomes (Figure 1A), dephosphorylation of eIF4E, 4E-BP1, S6 and an increased association of eIF4E and 4E-BP1 [11,13]. Upon restoration of isotonic conditions the polysomal fraction is rapidly reconstituted (Figure 1B and [11]). Using this methodology it was possible to examine what effect rapamycin had on the recruitment of mRNA populations onto free ribosomes following very short drug exposure times. It was in substance an in-vivo competition assay performed under two defined physiological conditions. Drug treatment appeared to delay recruitment as evidenced by the reduction in the heavy polysome peak (≥ 6 ribosomes: compare Figure 1B and 1C), and this effect was correlated with a modification of the downstream signalling targets of mTOR, including 4E-BP1 and S6 kinase. (Figure 1D, compare the second and third lanes). This confirmed that despite the relatively short time of exposure to rapamycin, the recruitment assay monitored transcript:ribosome re-association under two conditions in which elf4E availability was altered.

**A profiling screen identifies changes in the light and heavy polysomal mRNA populations**

Equal amounts of RNA isolated from the light (2 to 5 ribosomes) and heavy (> 5 ribosomes) polysomal frac-
tions were used to probe the Affymetrix Gene Chip U133 Plus 2. Triplicate independent gradients under each experimental condition were examined. After data analysis, two subpopulations of transcripts were clearly discriminated: those dominant in the light polysomal fraction and those dominant in the heavy polysomal fraction, an important criterion since it validated the initial experimental approach (Figure 2A). Despite the fact that the polysomal peaks were smaller in the presence of rapamycin, consistent with a global repression, the two sub-populations were essentially conserved (i.e. no major movement of mRNA populations between the two fractions as a consequence of the treatment was evident). To analyse the data we used two approaches. Firstly, we filtered out all transcripts giving low probe set intensity values on the chip using the default settings of the Agilent analysis software package (values < 100). We then scored for mRNAs whose polysomal occupancy was altered by greater than \( \times 1.5 \) fold (listed in Additional File 1). This produced 437 transcripts within which was found the majority of the repressed TOP mRNAs (see below). Curiously, within this group of transcripts almost equal proportions were up and down-regulated (46% and 54%, respectively) (Figure 2B).

As a second approach to analyse the data we applied a \( \times 2.5 \) fold change cut-off point to the entire data set. The rationale for this alternative analysis is based upon the fact that many of the genes that are regulated at the level of translation are frequently transcribed at low levels. This includes proto-oncogenes and other factors that regulate cell growth [14]. The majority of these transcripts are found within the lower intensity range and we therefore tested if meaningful information could be extracted from

Figure 1

**Ribosomal re-recruitment in the presence of rapamycin.** (A). High salt provokes a rapid disaggregation of polysomes. (B). Upon restoration of isotonic conditions the polysomal fraction is reconstituted (C). Pre-treatment with rapamycin delays the re-recruitment of ribosomes. The position of the ribonucleoprotein (RNP), the monosomal (Mono) and polysomal (Poly) fractions are indicated. (D) Western blot analysis of phospho-4EBP-1, 4EBP-1, phospho-S6K, S6K, and actin was performed on extracts isolated under the different conditions depicted in panels (A); (B) and (C).
**Figure 2**

**Microarray analysis.** (A). Hierarchical clustering of relative expression. Each column represents the different conditions. On the right the vertical bar indicates probe set intensity values (indicated as Expression) in arbitrary units. The zero value indicates absence, with blue indicating a low level and red a high level of expression (the maximum value being fixed as 5). The vertical brackets on the right indicate that transcripts have been grouped into those over-represented in the light polysomes (lower) or in the heavy polysomes (upper). (B). After removal of probe set intensity values < 100, and the application of a ×1.5 fold cut-off, the regulated genes were classified into four groups. The values indicate the number of transcripts in each group. (C). In a second approach, a ×2.5 fold cut-off was applied. (D) and (E). Functional classification using Gene Ontology of the genes either up-regulated or down-regulated (as depicted in panel b and in Additional File 1, and panel c and in Additional File 2, respectively). The unknown fraction represents genes not annotated in the Gene Ontology database.
this region by applying a more stringent selection. We observed that 1160 mRNAs (3.8%) showed increased or decreased polysomal distribution in the presence of rapamycin, suggesting that in this small fraction of transcripts the affinity for the cap binding complex was changed (Figure 2C and Additional File 2). Over 2/3 of the mRNAs responding to the drug were down-regulated, whereas 1/3 showed increased polysomal occupancy relevant to the non-treated control. Only a few transcripts were regulated in both the heavy and the light polysomes (55 mRNAs) (Figure 2C). These results are not unlike those reported in a translational profiling study performed on the two tumoural cell lines, LAPC-4 (prostate cancer) and U87 (glioblastoma). Applying the 2.5 fold cut-off point, ca. 6% of the 3,000 transcripts screened showed altered polysomal occupancy, and amongst these, 60% were down-regulated and 40% up-regulated [7].

Those mRNAs showing significant redistributions (both increased and decreased: as listed in Additional Files 1 and 2) were then plotted onto cellular networks using the GO ontology (Affymetrix) software package. Results revealed that transcripts up- or down-regulated affected more or less the same biological processes (Figure 2D and 2E). However, using the Ingenuity pathway analysis a number of features were immediately evident in the rapamycin treated cells: (a) A group of mRNAs involved in the inflammatory response were regulated, consistent with the immunosuppressive activity of rapamycin. Interestingly, we also observed down-regulation of several transcripts linked to phagocytosis. It has recently been reported that rapamycin down-regulates phagocytosis in a murine macrophage cell line (Table 1) [15]. (b) We observed a number of mRNAs involved in cell growth and proliferation. Among them, a number of anti-apoptotic mRNAs were up-regulated (e.g. relA and mdm2), whereas pro-apoptotic ones were down-regulated (e.g. fas, faslg and faf1) (Table 1). This is consistent with the observation that rapamycin did not induce apoptosis in MRC-5 cells even after extended exposure (unpublished observations), and corroborated recent studies showing the anti-apoptotic properties of rapamycin [16,17].

Rapamycin is known to have a marked effect on the expression of a subset of transcripts referred to as terminal oligopyrimidine (TOP) mRNAs [18]. This includes ribosomal protein mRNAs (estimated to be ~15% of the total cellular mRNA) and translation elongation factors. In previous translational profiling studies, a number of TOP mRNAs were clearly repressed. We also observed repression of ribosomal transcripts, although the effects were less extensive than in the earlier reports. This may reflect both the shorter drug exposure times and the experimental approach that was employed (i.e. mRNA re-recruitment onto free ribosomes). With the cut-off threshold at ×2.5 fold we observed down regulation of rpl14 and rpl21 in the light polysomes and rpl0 in the heavy polysomes (ribosomal protein large). However, if the threshold was reduced to ×1.5 fold the number of hits significantly increased. Most significantly, ribosomal transcripts were only ever observed down-regulated (Table 2 and Additional File 1).

Independent confirmation of the array results by RT-PCR

With the aim of validating the microarray we performed real-time RT-PCR on selected transcripts across the spectrum of probe set intensities (Figure 3A). We were particularly interested in those transcripts that gave low probe set values. For the RT-PCR, RNA was extracted from a fourth independent experiment. Nine mRNAs were initially selected (Transcripts up-regulated = qki, rbm7, ormdl1. Transcripts down-regulated = fas, rbm17, pappa, Transcripts not regulated = β-actin, L27, cyclin D1: see Additional Files 1 and 2). Transcripts from the lower values of the data set (see Additional File 2 and Figure 3A) were selected because of the large fold difference between the rapamycin and DMSO control (> 2.5 fold). The results, with the exception of those obtained with the pappa transcript, largely confirmed the micro-array data (Figure 3B). This was particularly encouraging for transcripts such as those coding for QKI and FAS, indicating that application of the ×2.5 fold cut-off approach permitted the extraction of useful hits even in the lower end of the probe intensity set (Figure 3A). Note that the absence of a light RT-PCR value for RBM17 simply reflected its low levels in this fraction (Ct > 35 cycles). The microarray study also indicated that this transcript was regulated only within the heavy polysomal fraction, a result confirmed by the RT-PCR. In addition, these studies also demonstrated that no significant changes in total mRNA levels had occurred within the selected transcripts as a consequence of drug exposure (Figure 3B).

Discussion

In this technical report, we have outlined a novel approach to translational profiling that follows the impact of a drug on the de-novo re-association of mRNAs and ribosomes in living cells in culture. An intracellular pool of free ribosomes was generated by a short hypertonic shock. Although this undoubtedly induced a stress response, previous work has demonstrated that the translation initiation machinery recovers very rapidly after the cells are transferred back to isotonic conditions as monitored by the reconstitution of the polysomal fraction [11,13]. The rapidity at which the polysomes are reformed has permitted us to examine the effect of a drug on this process using a short time window of exposure. This has the effect of limiting undesirable secondary effects that arise upon extended exposure, an effect highlighted by the drug selected for this study, namely rapamycin (see Intro-
Table 1: List of transcripts regulated by rapamycin (Ingenuity classification)

### Inflammation

| Upregulated       | Downregulated       |
|-------------------|---------------------|
| **Inflammation**  |                     |
| **Upregulated**   | **Downregulated**   |
| apobec3f          | lst1                |
| blink             | mdm2                |
| cald1             | oas1                |
| cmklr1            | parvg               |
| ctna4             | pagf                |
| cyp3a4            | rela                |
| fyn               | sat1                |
| hla-g             | tcf12               |
| ifih1             | tfap4               |
| ifna2             | thbs1               |
| il16              | trl7                |
| il28b             | unc119              |
| itga4             | vec1l               |
| apoBec3F          | LST1                |
| Blink             | MDM2                |
| CalD1             | OAS1                |
| CML-1             | PARV                 |
| CTN A4            | PAGF                |
| CYP3A4            | RELA                |
| FYN               | SAT1                |
| HLA-G             | TCF12               |
| IFIH1             | TFAP4               |
| IFNA2             | THBS1               |
| IL16              | TRL7                |
| IL28B             | UNC119              |
| ITGA4             | VEC1L               |
| Adora2A           | Ifit1r              |
| Acvr1b            | Eraf                |
| Ctna4             | Rela                |
| Ctx              | Rnase1              |
| Cyp2e1            | Spp1                |
| Cyp3a4            | Tfar4               |
| Erbb3             | Thbs1               |
| Erg               | Traf4               |
| Fyn               | Zmym2               |
| ApoBec3F          | LST1                |
| Blink             | MDM2                |
| CalD1             | OAS1                |
| CML-1             | PARV                 |
| CTN A4            | PAGF                |
| CYP3A4            | RELA                |
| FYN               | SAT1                |
| HLA-G             | TCF12               |
| IFIH1             | TFAP4               |
| IFNA2             | THBS1               |
| IL16              | TRL7                |
| IL28B             | UNC119              |
| ITGA4             | VEC1L               |
| Adora2A           | Ifit1r              |
| Acvr1b            | Eraf                |
| Ctna4             | Rela                |
| Ctx              | Rnase1              |
| Cyp2e1            | Spp1                |
| Cyp3a4            | Tfar4               |
| Erbb3             | Thbs1               |
| Erg               | Traf4               |
| Fyn               | Zmym2               |

### Cell growth and proliferation

| Upregulated       | Downregulated       |
|-------------------|---------------------|
| **Cell growth and proliferation** |                     |
| **Upregulated**   | **Downregulated**   |
| Adam12            | Mdm2                |
| Blink             | Pappa               |
| Cdc2l5            | Rag2                |
| Ctna4             | Rela                |
| Cxcr4             | S100b               |
| Erbb3             | Ss18                |
| Fyn               | Tcf12               |
| Hla-g             | Thbs1               |
| Ifi1r             | Unc119              |
| Itga4             | Vc1l                |
| Adam12            | MDM2                |
| Blink             | Pappa               |
| Cdc2l5            | Rag2                |
| Ctna4             | Rela                |
| Cxcr4             | S100b               |
| Erbb3             | Ss18                |
| Fyn               | Tcf12               |
| Hla-g             | Thbs1               |
| Ifi1r             | Unc119              |
| Itga4             | Vc1l                |
| Adam12            | MDM2                |
| Blink             | Pappa               |
| Cdc2l5            | Rag2                |
| Ctna4             | Rela                |
| Cxcr4             | S100b               |
| Erbb3             | Ss18                |
| Fyn               | Tcf12               |
| Hla-g             | Thbs1               |
| Ifi1r             | Unc119              |
| Itga4             | Vc1l                |

### Cell death

| Upregulated       | Downregulated       |
|-------------------|---------------------|
| **Cell death**    |                     |
| **Upregulated**   | **Downregulated**   |
| Blink             | Iga2                |
| Cdk6              | Mdm2                |
| Ctna4             | Rag2                |
| Cull              | Rela                |
| Cxcr4             | Rnase1              |
| Cyp2e1            | Spp1                |
| Cyp3a4            | Tfar4               |
| Erbb3             | Thbs1               |
| Erg               | Traf4               |
| Fyn               | Zmym2               |
| Blink             | IGA2                |
| Cdk6              | MDM2                |
| Ctna4             | Rag2                |
| Cull              | Rela                |
| Cxcr4             | Rnase1              |
| Cyp2e1            | Spp1                |
| Cyp3a4            | Tfar4               |
| Erbb3             | Thbs1               |
| Erg               | Traf4               |
| Fyn               | Zmym2               |

### Phagocytosis

| Upregulated       | Downregulated       |
|-------------------|---------------------|
| **Phagocytosis**  |                     |
| **Upregulated**   | **Downregulated**   |
| Blink             | Iga2                |
| Cdk6              | Mdm2                |
| Ctna4             | Rag2                |
| Cull              | Rela                |
| Cxcr4             | Rnase1              |
| Cyp2e1            | Spp1                |
| Cyp3a4            | Tfar4               |
| Erbb3             | Thbs1               |
| Erg               | Traf4               |
| Fyn               | Zmym2               |
| Blink             | IGA2                |
| Cdk6              | MDM2                |
| Ctna4             | Rag2                |
| Cull              | Rela                |
| Cxcr4             | Rnase1              |
| Cyp2e1            | Spp1                |
| Cyp3a4            | Tfar4               |
| Erbb3             | Thbs1               |
| Erg               | Traf4               |
| Fyn               | Zmym2               |
duction). The short exposure time warranted a drug concentration higher than that generally used in animal studies [19], however, some studies in cell culture systems have employed rapamycin concentrations as high as 15–20 μM before observing an impact on cell growth [20]. The selection was also dictated too by the fact that rapamycins’ effect on translation initiation has been extensively studied. We have demonstrated that this approach can be coupled to a high-throughput analysis of the polysomal transcript populations.

Treatment with rapamycin limits the availability of eIF4E via its sequestration into an inactive complex with the hypophosphorylated 4E-BPs. Such a scenario represses global translation rates but with an effect more marked on those mRNAs containing structured 5' UTRs and those containing TOP elements. Indeed, when TOP containing transcripts were identified in our array they were always down-regulated (Table 2). Additionally, although the polysome profiles demonstrated an overall translational repression, the position of the vast majority of mRNAs on the gradient (i.e. the transcript populations in both the heavy and light polysomes) was largely unperturbed by the drug (i.e. there was little movement of transcripts from heavy to light polysomes, a somewhat unanticipated response), indicating that the affinity of re-recruitment of ribosomes onto these mRNAs (as reflected by the number of ribosomes per transcript) was largely unchanged.

A number of translational profiling studies examining the effect of rapamycin in mammalian cells have already been reported. In one of these, the effect of rapamycin on the polysomal distribution of mRNAs was demonstrated to be coupled to the activity of AKT [7], a result that demonstrates the extent to which a drugs effect can be modulated by the physiological status of the cell. This interpretation has become even more convoluted following the observation that prolonged rapamycin treatment may inhibit AKT signalling by interfering with the assembly of the second mTOR complex, mTORC2 [21]. However, with regards to the two transcripts characterised in this work as strongly up-regulated, namely cyclin D1 and c-myc, the former was down-regulated in our screen (×1.5 fold), and the latter gave values that were not considered statistically significant. Other studies have also failed to observe changes in the polysomal occupancy of the cyclin D1 mRNA in the presence of rapamycin [9,10,22]. These differences may reflect the cell lines and/or the experimental procedures employed. Both cyclin D1 and c-myc were proposed to carry IRESes within the 5' UTR, and IRES activity has been reported to show cell type specificity linked to the availability of ITAFs (IRES Trans-Acting Factors) [23]. Furthermore, the responsiveness of these IRESes to rapamycin

| Table 1: List of transcripts regulated by rapamycin (Ingenuity classification) (Continued) |
|----------------------------------|----------------------------------|
| **Upregulated** | **Downregulated** |
| cd36 | klf2 |
| fas | mpo |
| fcgr2a | pla2g6 |
| hck | syk |
| itgb3 | |

The 1160 mRNAs identified in the microarray screen (as listed in Additional File 2) were plotted onto biological networks using the Ingenuity Pathway Analysis Software package. Those whose protein products are involved in inflammation, phagocytosis, cell growth/proliferation and cell death are listed.

| Table 2: List of TOP mRNAs detected in the array. |
|----------------------------------|-------------------|-----------------|
| **LIGHT POLYSOME UP** | **LIGHT POLYSOME DOWN** | **HEAVY POLYSOME DOWN** |
| (NONE) | rpl5 (-1.5) | rplP0 (-2.7) |
| | rpl14 (-2.5) | rpl36 (-1.5) |
| | rpl21 (-5.1) | eef2 (-1.5) |
| **HEAVY POLYSOME UP** | rpl38 (-1.5) | (translation elongation factor) |
| (NONE) | rps11 (-2.1) | |
| | rps19 (-1.5) | |
| | rps21 (-2.1) | |
| | rps28 (-1.6) | |
| | eftuD1 (-5.5) | (translation elongation factor) |
Figure 3
Real-Time RT-PCR analysis. (A). A schematic representation of the intensity values of transcripts selected for the RT-PCR validation. In the upper panel, the horizontal bars represented the value range for each mRNA on the array. The lower panel plots the distribution of regulated genes (*2.5 fold cut-off selection) relative to the probe set values. (B). RT-PCR values were normalised to those obtained from two housekeeping genes and the fold change indicates the difference in the DMSO and rapamycin values after normalisation. The DMSO value was arbitrarily set at 1. The results are compared with those obtained from the microarray. The variation in the total mRNA extracted is also represented. The 2.5 fold difference used for the screening is represented by the dotted lines (2.5 and 0.4). Each bar is representative of 2 independent RT-PCR assays performed in triplicate. Bars indicate the SEM.
was shown to be tightly coupled to the cellular activity of the AKT and RAF/MEK/ERK signalling cascades, features that may also show cell-type variation [24]. However, the slight reduction that we observed in the polysomal levels of the cyclin D1 mRNA would be consistent with other reports indicating that its expression was sensitive to the levels of eIF4E [25,26]. Finally, the earlier profiling study followed changes in the steady-state population after extended exposure to the drug, whilst in the current work we have followed a competitive re-association. These processes may have altered initiation factor requirements, which could impact on the mRNA population that respond. Indeed, it has been proposed that eIF4GII but not eIF4GI is required for re-initiation subsequent to a hypertonic shock [27]. Nonetheless, a listing of transcripts detected in both studies demonstrated that the majority behaved similarly (see Additional File 3).

Conclusion
In summary, a major effort is underway to use high density microarray profiles to study how different drug regimes impact on the polysomal mRNA populations. These studies provide insights into how cellular gene expression is regulated at the level of translation initiation, the rate limiting step in protein expression. Changes in this read-out are a very rapid cellular response to physiological perturbations. The method that we have outlined permits a specific analysis of how a drug impacts on transcript-ribosome association. This early response almost certainly conditions subsequent cell behaviour during extended exposure. The choice of rapamycin for this "proof-of-principle" work was not arbitrary since the impact of this drug on translation initiation has been extensively studied. The technique offers the possibility of establishing molecular fingerprints for different tumour derived cell types and drug regimes [28]. In addition, it provides a very powerful technique to analyse the early events in translational control at the level of mRNA:ribosome association.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RG and PJ-G prepared the polysomal RNA for the microarray analysis. RG and TA were involved in the analysis of the microarray data. RG and LM performed the RT-PCR control. JC prepared the manuscript. All authors have read and approved the manuscript.

Acknowledgements
The work was supported by grants from the "La Ligue Genevoise Contre le Cancer" and the "Fonds National Suisse". We thank Dr. Jean-Dominique Vassalli and Dr. Beatrice Conne for use of the gradient apparatus, and the input of Dr. Bernadino Conrad. Finally, we thank Dr. Patrick Descombe, Dr. Olivier Schaad and Didier Chollet from the Genomics Platform of the NCCR program "Frontiers in Genetics" http://www.frontiers-in-genetics.org/genomics.htm for their invaluable help in performing and analyzing the microarray experiments.

References
1. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liao I, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koletso M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5:e8.
2. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N: Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999, 13:1422-1437.
3. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000, 103:253-262.
4. Abraham RT, Wiederrecht GJ: Immunopharmacology of rapamycin. Annu Rev Immunol 1996, 14:483-510.
5. Shamiy AF, Nghiem P, Schreiber SL: Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell 2003, 12:271-280.
6. Peng T, Golub TR, Sabatini DM: The Immunosuppressant Rapamycin Mimics a Starvation-Like Signal Distinct from Amino Acid and Glucose Deprivation. Mol Cell Biol 2002, 22:5575-5584.
7. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu J, Sawyers CL, Lichtenstein AK: AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression. Journal of Biological Chemistry 2004, 279:2737-2746.
8. Grospellier A, Bowman J, Pradet-Balade B, Puravs E, Hanash S, Garcia-Sanz Jose, Beretta L: Global and Specific Translational Control by Rapamycin in T Cells Uncovered by Microarrays and Proteomics. Journal of Biological Chemistry 2002, 277:21175-21184.

9. Mamane Y, Petrováuskis E, Martineau Y, Sato TA, Larsson O, Rajashekhar VK, Sonenberg N: Epigenetic Activation of a Subset of mRNAs by elf4E Explains Its Effects on Cell Proliferation. PLoS ONE 2007, 2:e242.

10. Bilanges B, Gonzalez-Barrett R, Kolesnichenko M, Skinner C, Nair M, Chen M, Stokoe D: Tuberous Sclerosis Complex Proteins 1 and 2 Control Serum-Dependent Translation in a TOP-Dependent and -Independent Manner. Mol Cell Biol 2007, 27:5746-5764.

11. Naegle S, Morley SJ: Molecular Cross-talk between MEK1/2 and mTOR Signaling during Recovery of 293 Cells from Hypertonic Stress. Journal of Biological Chemistry 2004, 279:46023-46034.

12. Djoudi H, Genolet R, Jaquier-Gubler P, Curran J: Alternatively spliced isoforms of the human elk-1 mRNA within the 5' UTR: implications for ELK-1 expression. Nucleic Acids Res 2007, 35:4649-4663.

13. Morley SJ, Naegle S: Phosphorylation of Eukaryotic Initiation Factor (eIF) 4E Is Not Required for de Novo Protein Synthesis following Recovery from Hypertonic Stress in Human Kidney Cells. Journal of Biological Chemistry 2002, 277:32855-32859.

14. Willis AE: Translational control of growth factor and proto-oncogene expression. Int J Biochem Cell Biol 1999, 31:73-86.

15. Ganesan LP, Wei G, Pengal RA, Moldovan L, Moldovan N, Ostrouski MC, Trindandapani S: The Serine/Threonine Kinase Akt Promotes Fc(gamma) Receptor-mediated Phagocytosis in Murine Macrophages through the Activation of p70S6 Kinase. Journal of Biological Chemistry 2004, 279:54416-54425.

16. Ravikumar B, Berger Z, Vacher C, O’Kane CJ, Rubinsztein DC: Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006, 15:1209-1216.

17. Noh WC, Mondeire WH, Peng J, Jiao W, Zhang H, Dong JG, Mills GB, Hung MC, Mercier-Bernstam F: Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clin Cancer Res 2004, 10:1013-1023.

18. Hamilton TL, Stoneley M, Spriggs KA, Bushell M: TOPs and their regulation. Biochem Soc Trans 2006, 34:12-16.

19. Buist AM, Fichtner M, Armstrong J, Sharr M, Sehgal SN: Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat. Transplantation 1996, 62:1109-1112.

20. Johansen NL, Segerskov L, Orrego A, Ellman L, Henriksson M, Kagedal B, Ekborg S, Svennblomsson B, Kogner P: Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008, 27:2910-2922.

21. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.

22. Larsson O, Perlman DM, Fan D, Reilly CS, Petersen M, Dahlgren C, Liang Z, Li S, Polunovsky VA, Wahlestedt C, Bitterman PB: Apoptosis resistance downstream of elf4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res 2006, 34:4375-4386.

23. Pilipenko EV, Povetkov TV, Kolupaeva VG, Khitrina EV, Poperechnaya AN, Agol VI, Hellen CU: A cell cycle-dependent protein serves as a template-specific translation initiation factor. Genes Dev 2005, 19:2028-2045.

24. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J: Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway. Journal of Biological Chemistry 2005, 280:10964-10973.

25. Rosenwald IB, Kaspar R, Rousseau D, Gehrie L, Leboulch P, Chen J, Schmidt EV, Sonenberg N, London IM: Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995, 270:21176-21180.

26. Rousseau D, Kaspar R, Rosenwald I, Gehrie L, Sonenberg N: Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 1996, 93:1065-1070.

27. Castello A, Alvarez E, Carrasco L: Differential Cleavage of elf4G1 and elf4GII in Mammalian Cells: EFFECTS ON TRANSLATION. Journal of Biological Chemistry 2006, 281:33206-33216.

28. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragan J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febyo P, Lancaster J, Nevins JR: Genomic signatures guide the use of chemotherapeutics. Nat Med 2006, 12:1294-1300.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1755-8794/1/33/prepub